Rostaporfin is under clinical development by TuHURA Biosciences and currently in Phase III for Metastatic Breast Cancer. According to GlobalData, Phase III drugs for Metastatic Breast Cancer have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Rostaporfin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rostaporfin overview
Rostaporfin (REM-001) is under development for the treatment of cutaneous metastatic breast cancer, human epidermal growth factor receptor 2 negative breast cancer (HER2 negative breast cancer), human epidermal growth factor receptor 2 positive breast cancer (HER2 positive breast cancer), basal cell carcinoma with nevus syndrome. The drug candidate is a light-activated cytotoxic drug. It is administered through intravenous route. It is a new chemical entity (NCE).
It was also under development for the treatment of arteriovenous fistula, metastatic lung cancer bile duct cancer, classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), metastatic ovarian cancer, metastatic colon cancer and prevention of access graft disease in hemodialysis patients.
TuHURA Biosciences overview
Kintara Therapeutics Inc (Kintara) is a clinical stage drug development bio pharmaceutical company. It engages in the development and commercialization of new cancer therapies. The company offers VAL-083, a small molecule chemotherapy used for the treatment of refractory glioblastoma multiforme(GMB) of brain cancer. Kintara explores VAL-083 as a therapy for solid tumors and front-line GBM including ovarian cancer and non-small cell lung cancer (NSCLC). The company offers its produts and services to lung cancer, ovarian cancer, chronic myeloid leukemia, brain cancers and lung cancer. Kintara provides warrants services, pre-clinical testing and clinical trials, among others. It operates in the US and Canada. Kintara Pharmaceuticals is headquartered in San Diego, California, United States.
For a complete picture of Rostaporfin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
